[Skip to Content]
[Skip to Content Landing]

Evaluation of Cannabis Use Among US Adults During the COVID-19 Pandemic Within Different Legal Frameworks

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

The COVID-19 pandemic caused disruptions to treatment of substance use disorder, the availability of drugs, and other social factors that influence drug use.1 In June 2020, more than 10% of adults had started or increased substance use to cope with the pandemic,2 which could include using cannabis. The divergence in state-by-state policies governing cannabis sales in the US could create differences in who might use cannabis and for what reasons, particularly because stress can be a catalyst for substance use. In this cross-sectional study, we analyzed changes in prevalence of cannabis use during the pandemic within different legal frameworks and evaluated differences in associated behaviors.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: September 22, 2022.

Published: November 7, 2022. doi:10.1001/jamanetworkopen.2022.40526

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Black JC et al. JAMA Network Open.

Corresponding Author: Joshua C. Black, PhD, Rocky Mountain Poison & Drug Safety, Denver Health and Hospital Authority, 777 Bannock St, MC 0180, Denver, CO 80204 (joshua.black@rmpds.org).

Author Contributions: Dr Black had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Black, Amioka, Iwanicki, Monte.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Black, Amioka, Iwanicki, Monte.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Black, Amioka.

Administrative, technical, or material support: Black, Iwanicki, Dart.

Supervision: Iwanicki, Dart, Monte.

Conflict of Interest Disclosures: Dr Monte reported serving on the scientific advisory board for Anebulo Pharmaceuticals and receiving personal fees from Anebulo Pharmaceuticals. No other disclosures were reported.

Additional Information: The RADARS System is the property of the Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. The DHHA retains exclusive ownership of all data, databases and systems.

References
1.
Volkow  ND , Blanco  C .  Research on substance use disorders during the COVID-19 pandemic.   J Subst Abuse Treat. 2021;129:108385. doi:10.1016/j.jsat.2021.108385PubMedGoogle ScholarCrossref
2.
Czeisler  MÉ , Lane  RI , Petrosky  E ,  et al.  Mental health, substance use, and suicidal ideation during the COVID-19 pandemic—United States, June 24-30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(32):1049-1057. doi:10.15585/mmwr.mm6932a1PubMedGoogle ScholarCrossref
3.
Black  JC , Rockhill  K , Forber  A ,  et al.  An online survey for pharmacoepidemiological investigation (survey of non-medical use of prescription drugs program): validation study.   J Med Internet Res. 2019;21(10):e15830. doi:10.2196/15830PubMedGoogle ScholarCrossref
4.
Roberts  A , Rogers  J , Mason  R ,  et al.  Alcohol and other substance use during the COVID-19 pandemic: A systematic review.   Drug Alcohol Depend. 2021;229(Pt A):109150. doi:10.1016/j.drugalcdep.2021.109150PubMedGoogle ScholarCrossref
5.
Jalan  M , Riehm  K , Nekkanti  M ,  et al.  Burden of mental distress in the United States is associated with delayed medical visits and missed prescription refills during the COVID-19 pandemic.   Prev Med. 2022;163:107195. doi:10.1016/j.ypmed.2022.107195PubMedGoogle ScholarCrossref
6.
Currie  JM , Schnell  MK , Schwandt  H , Zhang  J .  Prescribing of opioid analgesics and buprenorphine for opioid use disorder during the COVID-19 pandemic.   JAMA Netw Open. 2021;4(4):e216147. doi:10.1001/jamanetworkopen.2021.6147PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close